The guidelines do not recommend adjuvant therapy for PDGFRA D842V-mutated GISTs [2,4,59], nor is the therapy indicated for GISTs without KIT or PDGFRA mutations (“wild-type GIST”) because of the relatively indolent nature as well as their lack of imatinib responsiveness [59]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.